Outcomes of patients with borderline resectable and resectable pancreatic adenocarcinoma treated with neoadjuvant three-week course chemoradiotherapy using capecitabine-based versus gemcitabine-based concurrent chemotherapy

Shane S. Neibart, Swati Mamidanna, Anupama Chundury, Mutlay Sayan, H. Richard Alexander, David A. August, Lyudmyla D. Berim, Patrick M. Boland, Miral S. Grandhi, Prateek Gulhati, Howard S. Hochster, Russell C. Langan, Kristen R. Spencer, Timothy J. Kennedy, Matthew P. Deek, Salma K. Jabbour